{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:44:58Z","timestamp":1787579098060,"version":"build-2736575974"},"reference-count":133,"publisher":"Bentham Science Publishers Ltd.","issue":"21","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China, NSFC","doi-asserted-by":"publisher","award":["82173716"],"award-info":[{"award-number":["82173716"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Evodiamine (EVO) is a natural quinolone alkaloid firstly isolated from the fruit of Evodia rutaecarpa,\nwhich is one of the most frequently used traditional Chinese herb for treating a variety of ailments,\nincluding headaches, abdominal pain, vomiting, diarrhea, amenorrhea difficult menstruation,\npostpartum hemorrhage, and other diseases. Latest pharmacological studies showed that EVO possesses a\nbroad spectrum of pharmacological activities through different mechanisms. However, its moderate activities\nand poor physicochemical properties have hampered its clinical application. In this regard, the\nmodification of EVO aiming at seeking derivatives with more potency and better physicochemical properties\nhas been extensively emerging. These derivatives exhibit diverse biological activities, including\nantitumor, anti-Alzheimer's disease, anti-pulmonary hypertension, anti-fungi, and thermogenic activities\nvia a variety of mechanisms. Moreover, they are described to act as single, dual, or multiple inhibitors or\nagonists of many proteins, such as topoisomerase I, topoisomerase II, tubulin, histone deacetylase,\nsirtuins, butyrylcholinesterase, phosphodiesterase 5, and transient receptor potential vanilloid 1. However,\nhitherto, there is no comprehensive review to systematically summarize the derivatives of EVO. Considering\nthis perspective, this paper aims to provide a comprehensive description of them by focusing on\ntheir diverse biological activities. For each biological activity, the mechanisms and the main structureactivity\nrelationships (SARs) will be presented in cases where adequate information is available. Finally,\nfuture directions of this class of compounds will be discussed. This review will be helpful in understanding\nand encouraging further exploration of EVO.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1389557522666220404090835","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T02:51:01Z","timestamp":1649127061000},"page":"2680-2701","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Evodiamine: A Privileged Structure with Broad-ranging Biological Activities"],"prefix":"10.2174","volume":"22","author":[{"given":"Wenwu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People\u2019s Republic of\nChina"},{"name":"School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People\u2019s\nRepublic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People\u2019s Republic of\nChina"},{"name":"School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People\u2019s\nRepublic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People\u2019s Republic of\nChina"},{"name":"Department of Pharmacy, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, People\u2019s\nRepublic of China"},{"name":"School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People\u2019s Republic of\nChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, People\u2019s\nRepublic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, People\u2019s Republic of\nChina"},{"name":"School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People\u2019s\nRepublic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","volume":"83","author":"Newman D.J.","year":"2020","unstructured":"Newman D.J.; Cragg G.M.; Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019. J Nat Prod 2020,83(3),770-803","journal-title":"J Nat Prod"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","volume":"79","author":"Newman D.J.","year":"2016","unstructured":"Newman D.J.; Cragg G.M.; Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 2016,79(3),629-661","journal-title":"J Nat Prod"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1021\/np200906s","volume":"75","author":"Newman D.J.","year":"2012","unstructured":"Newman D.J.; Cragg G.M.; Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012,75(3),311-335","journal-title":"J Nat Prod"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/np068054v","volume":"70","author":"Newman D.J.","year":"2007","unstructured":"Newman D.J.; Cragg G.M.; Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007,70(3),461-477","journal-title":"J Nat Prod"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1021\/np030096l","volume":"66","author":"Newman D.J.","year":"2003","unstructured":"Newman D.J.; Cragg G.M.; Snader K.M.; Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003,66(7),1022-1037","journal-title":"J Nat Prod"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/np9604893","volume":"60","author":"Cragg G.M.","year":"1997","unstructured":"Cragg G.M.; Newman D.J.; Snader K.M.; Natural products in drug discovery and development. J Nat Prod 1997,60(1),52-60","journal-title":"J Nat Prod"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"10800","DOI":"10.1002\/anie.201007004","volume":"50","author":"Wetzel S.","year":"2011","unstructured":"Wetzel S.; Bon R.S.; Kumar K.; Waldmann H.; Biology-oriented synthesis. Angew Chem Int Ed Engl 2011,50(46),10800-10826","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1021\/ar100014h","volume":"43","author":"Bon R.S.","year":"2010","unstructured":"Bon R.S.; Waldmann H.; Bioactivity-guided navigation of chemical space. Acc Chem Res 2010,43(8),1103-1114","journal-title":"Acc Chem Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1749-8546-6-6","volume":"6","author":"Liao J.F.","year":"2011","unstructured":"Liao J.F.; Chiou W.F.; Shen Y.C.; Wang G.J.; Chen C.F.; \nAnti-inflammatory and anti-infectious effects of \nEvodia rutaecarpa\n(Wuzhuyu) and its major bioactive components.\n Chin Med 2011,6(1),6","journal-title":"Chin Med"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/molecules13020272","volume":"13","author":"Lee S.H.","year":"2008","unstructured":"Lee S.H.; Son J-K.; Jeong B-S.; Jeong T-C.; Chang H.W.; Lee E-S.; Jahng Y.; Progress in the studies on rutaecarpine. Molecules 2008,13,272-300","journal-title":"Molecules"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s000110050512","volume":"48","author":"Moon T.C.","year":"1999","unstructured":"Moon T.C.; Murakami M.; Kudo I.; Son K.H.; Kim H.P.; Kang S.S.; Chang H.W.; \nA new class of COX-2 inhibitor, rutaecarpine from \nEvodia rutaecarpa\n.\n Inflamm Res 1999,48(12),621-625","journal-title":"Inflamm Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1021\/np960495z","volume":"60","author":"Chiou W.F.","year":"1997","unstructured":"Chiou W.F.; Sung Y.J.; Liao J.F.; Shum A.Y.; Chen C.F.; Inhibitory effect of dehydroevodiamine and evodiamine on nitric oxide production in cultured murine macrophages. J Nat Prod 1997,60(7),708-711","journal-title":"J Nat Prod"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejphar.2006.10.002","volume":"555","author":"Ko H.C.","year":"2007","unstructured":"Ko H.C.; Wang Y.H.; Liou K.T.; Chen C.M.; Chen C.H.; Wang W.Y.; Chang S.; Hou Y.C.; Chen K.T.; Chen C.F.; Shen Y.C.; \nAnti-inflammatory effects and mechanisms of the ethanol extract of \nEvodia rutaecarpa\nand its bioactive components on neutrophils and microglial cells.\n Eur J Pharmacol 2007,555(2-3),211-217","journal-title":"Eur J Pharmacol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/SHK.0b013e31819940cb","volume":"32","author":"Liu Y.N.","year":"2009","unstructured":"Liu Y.N.; Pan S.L.; Liao C.H.; Huang D.Y.; Guh J.H.; Peng C.Y.; Chang Y.L.; Teng C.M.; Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7. Shock 2009,32(3),263-269","journal-title":"Shock"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.3390\/ijms19113403","volume":"19","author":"Hu X.","year":"2018","unstructured":"Hu X.; Li D.; Chu C.; Li X.; Wang X.; Jia Y.; Hua H.; Xu F.; Antiproliferative effects of alkaloid evodiamine and its derivatives. Int J Mol Sci 2018,19(11),3403-3434","journal-title":"Int J Mol Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3892\/etm.2021.10762","volume":"22","author":"Luo C.","year":"2021","unstructured":"Luo C.; Ai J.; Ren E.; Li J.; Feng C.; Li X.; Luo X.; \nResearch progress on evodiamine, a bioactive alkaloid of \nEvodiae fructus\n: Focus on its anti-cancer activity and bioavailability. (Review). Exp Ther Med 2021,22(5),1327-1338","journal-title":"Exp Ther Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-3-319-41342-6_14","volume":"929","author":"Tan Q.","year":"2016","unstructured":"Tan Q.; Zhang J.; Evodiamine and its role in chronic diseases. Adv Exp Med Biol 2016,929,315-328","journal-title":"Adv Exp Med Biol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.fitote.2009.09.012","volume":"81","author":"Hu Y.","year":"2010","unstructured":"Hu Y.; Fahmy H.; Zjawiony J.K.; Davies G.E.; Inhibitory effect and transcriptional impact of berberine and evodiamine on human white preadipocyte differentiation. Fitoterapia 2010,81(4),259-268","journal-title":"Fitoterapia"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.brainres.2008.09.091","volume":"1247","author":"Shi J.","year":"2009","unstructured":"Shi J.; Yan J.; Lei Q.; Zhao J.; Chen K.; Yang D.; Zhao X.; Zhang Y.; Intragastric administration of evodiamine suppresses NPY and AgRP gene expression in the hypothalamus and decreases food intake in rats. Brain Res 2009,1247,71-78","journal-title":"Brain Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1016\/j.febslet.2009.10.046","volume":"583","author":"Wang T.","year":"2009","unstructured":"Wang T.; Wang Y.; Yamashita H.; \nEvodiamine inhibits adipogenesis \nvia\nthe EGFR-PKCalpha-ERK signaling pathway.\n FEBS Lett 2009,583(22),3655-3659","journal-title":"FEBS Lett"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1210\/en.2007-0467","volume":"149","author":"Wang T.","year":"2008","unstructured":"Wang T.; Wang Y.; Kontani Y.; Kobayashi Y.; Sato Y.; Mori N.; Yamashita H.; Evodiamine improves diet-induced obesity in a uncoupling protein-1-independent manner: Involvement of antiadipogenic mechanism and extracellularly regulated kinase\/mitogen-activated protein kinase signaling. Endocrinology 2008,149(1),358-366","journal-title":"Endocrinology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.phrs.2018.12.019","volume":"141","author":"Tian K.M.","year":"2019","unstructured":"Tian K.M.; Li J.J.; Xu S.W.; \nRutaecarpine: A promising cardiovascular protective alkaloid from \nEvodia rutaecarpa\n(Wu Zhu Yu).\n Pharmacol Res 2019,141,541-550","journal-title":"Pharmacol Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/aps.2010.230","volume":"32","author":"Yuan S.M.","year":"2011","unstructured":"Yuan S.M.; Gao K.; Wang D.M.; Quan X.Z.; Liu J.N.; Ma C.M.; Qin C.; Zhang L.F.; Evodiamine improves congnitive abilities in SAMP8 and APP(swe)\/PS1(\u0394E9) transgenic mouse models of Alzheimer\u2019s disease. Acta Pharmacol Sin 2011,32(3),295-302","journal-title":"Acta Pharmacol Sin"},{"key":"ref=24","first-page":"592-599","volume":"63","author":"Tominaga K.","year":"2005","unstructured":"Tominaga K.; Higuchi K.; Hamasaki N.; Tanigawa T.; Sasaki E.; Watanabe T.; Fujiwara Y.; Oshitani N.; Arakawa T.; Ishii E.; Tezuka Y.; Nagaoka T.; Kadota S.; Antibacterial activity of a Chinese herbal medicine, Gosyuyu (Wu-Chu-Yu), against Helicobacter pylori Nihon rinsho 2005,63,592-599","journal-title":"Helicobacter pylori Nihon rinsho"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"750513","DOI":"10.1093\/ecam\/nep238","volume":"2011","author":"Chiou W.F.","year":"2011","unstructured":"Chiou W.F.; Ko H.C.; Wei B.L.; \nEvodia rutaecarpa and three major alkaloids abrogate influenza A virus (H1N1)-induced chemokines production and cell migration. Evid Based Complement Alternat Med 2011,2011,750513","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1039\/b404506h","volume":"2","author":"Pearce L.V.","year":"2004","unstructured":"Pearce L.V.; Petukhov P.A.; Szabo T.; Kedei N.; Bizik F.; Kozikowski A.P.; Blumberg P.M.; Evodiamine functions as an agonist for the vanilloid receptor TRPV1. Org Biomol Chem 2004,2(16),2281-2286","journal-title":"Org Biomol Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1248\/cpb.39.690","volume":"39","author":"Kano Y.","year":"1991","unstructured":"Kano Y.; Zong Q.N.; Komatsu K.; Pharmacological properties of galenical preparation. XIV. Body temperature retaining effect of the Chinese traditional medicine, \u201cgoshuyu-to\u201d and component crude drugs. Chem Pharm Bull (Tokyo) 1991,39(3),690-692","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0091-3057(94)00317-C","volume":"50","author":"Tsai T.H.","year":"1995","unstructured":"Tsai T.H.; Lee T.F.; Chen C.F.; Wang L.C.; Thermoregulatory effects of alkaloids isolated from Wu-Chu-Yu in afebrile and febrile rats. Pharmacol Biochem Behav 1995,50(2),293-298","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0378-8741(89)90090-1","volume":"27","author":"Yamahara J.","year":"1989","unstructured":"Yamahara J.; Yamada T.; Kitani T.; Naitoh Y.; Fujimura H.; \nAntianoxic action of evodiamine, an alkaloid in \nEvodia rutaecarpa\nfruit.\n J Ethnopharmacol 1989,27(1-2),185-192","journal-title":"J Ethnopharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1248\/bpb.30.197","volume":"30","author":"Shin Y.W.","year":"2007","unstructured":"Shin Y.W.; Bae E.A.; Cai X.F.; Lee J.J.; Kim D.H.; \nIn vitro\nand \nin vivo\nantiallergic effect of the fructus of \nEvodia rutaecarpa\nand its constituents.\n Biol Pharm Bull 2007,30(1),197-199","journal-title":"Biol Pharm Bull"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1055\/s-2000-8615","volume":"66","author":"Kobayashi Y.","year":"2000","unstructured":"Kobayashi Y.; Nakano Y.; Hoshikuma K.; Yokoo Y.; Kamiya T.; \nThe bronchoconstrictive action of evodiamine, an indoloquinazoline alkaloid isolated from the fruits of \nEvodia rutaecarpa\n, on guinea-pig isolated bronchus: Possible involvement on vanilloid receptors.\n Planta Med 2000,66(6),526-530","journal-title":"Planta Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/S0026-0495(99)90241-X","volume":"48","author":"Lin H.","year":"1999","unstructured":"Lin H.; Tsai S.C.; Chen J.J.; Chiao Y.C.; Wang S.W.; Wang G.J.; Chen C.F.; Wang P.S.; Effects of evodiamine on the secretion of testosterone in rat testicular interstitial cells. Metabolism 1999,48(12),1532-1535","journal-title":"Metabolism"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jcb.22276","volume":"108","author":"Yu P.L.","year":"2009","unstructured":"Yu P.L.; Chao H.L.; Wang S.W.; Wang P.S.; Effects of evodiamine and rutaecarpine on the secretion of corticosterone by zona fasciculata-reticularis cells in male rats. J Cell Biochem 2009,108(2),469-475","journal-title":"J Cell Biochem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"8958","DOI":"10.3390\/ijms13078958","volume":"13","author":"Wang Z.","year":"2012","unstructured":"Wang Z.; Sun L.; Yu H.; Zhang Y.; Gong W.; Jin H.; Zhang L.; Liang H.; Binding mode pediction of evodiamine within vanilloid receptor TRPV1. Int J Mol Sci 2012,13(7),8958-8969","journal-title":"Int J Mol Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbrc.2010.09.122","volume":"402","author":"Yu H.","year":"2010","unstructured":"Yu H.; Tu Y.; Zhang C.; Fan X.; Wang X.; Wang Z.; Liang H.; Evodiamine as a novel antagonist of aryl hydrocarbon receptor. Biochem Biophys Res Commun 2010,402(1),94-98","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.1021\/jm100387d","volume":"53","author":"Dong G.","year":"2010","unstructured":"Dong G.; Sheng C.; Wang S.; Miao Z.; Yao J.; Zhang W.; Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents. J Med Chem 2010,53(21),7521-7531","journal-title":"J Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.3390\/molecules14051852","volume":"14","author":"Jiang J.","year":"2009","unstructured":"Jiang J.; Hu C.; \nEvodiamine: A novel anti-cancer alkaloid from \nEvodia rutaecarpa\n.\n Molecules 2009,14(5),1852-1859","journal-title":"Molecules"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"485042","DOI":"10.1155\/2012\/485042","volume":"2012","author":"Lu J.J.","year":"2012","unstructured":"Lu J.J.; Bao J.L.; Chen X.P.; Huang M.; Wang Y.T.; Alkaloids isolated from natural herbs as the anticancer agents. Evid Based Complement Alternat Med 2012,2012,485042","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3390\/molecules18021826","volume":"18","author":"Yu H.","year":"2013","unstructured":"Yu H.; Jin H.; Gong W.; Wang Z.; Liang H.; Pharmacological actions of multi-target-directed evodiamine. Molecules 2013,18(2),1826-1843","journal-title":"Molecules"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.fitote.2015.07.019","volume":"106","author":"Gavaraskar K.","year":"2015","unstructured":"Gavaraskar K.; Dhulap S.; Hirwani R.R.; Therapeutic and cosmetic applications of Evodiamine and its derivatives-A patent review. Fitoterapia 2015,106,22-35","journal-title":"Fitoterapia"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"153180","DOI":"10.1016\/j.phymed.2020.153180","volume":"68","author":"Li X.","year":"2020","unstructured":"Li X.; Ge J.; Zheng Q.; Zhang J.; Sun R.; Liu R.; Evodiamine and rutaecarpine from Tetradium ruticarpum in the treatment of liver diseases. Phytomedicine 2020,68,153180","journal-title":"Phytomedicine"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"113554","DOI":"10.1016\/j.ejmech.2021.113554","volume":"222","author":"Liu W.","year":"2021","unstructured":"Liu W.; Liu X.; Tian L.; Gao Y.; Liu W.; Chen H.; Jiang X.; Xu Z.; Ding H.; Zhao Q.; Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3\u03b2\/DYRK1A dual inhibitors for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 2021,222,113554","journal-title":"Eur J Med Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H.","year":"2021","unstructured":"Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249","journal-title":"CA Cancer J Clin"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ejmech.2019.03.034","volume":"171","author":"Liang X.","year":"2019","unstructured":"Liang X.; Wu Q.; Luan S.; Yin Z.; He C.; Yin L.; Zou Y.; Yuan Z.; Li L.; Song X.; He M.; Lv C.; Zhang W.; A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade. Eur J Med Chem 2019,171,129-168","journal-title":"Eur J Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejmech.2014.09.051","volume":"87","author":"Kaur R.","year":"2014","unstructured":"Kaur R.; Kaur G.; Gill R.K.; Soni R.; Bariwal J.; Recent developments in tubulin polymerization inhibitors: An overview. Eur J Med Chem 2014,87,89-124","journal-title":"Eur J Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"112831","DOI":"10.1016\/j.ejmech.2020.112831","volume":"208","author":"Peng X.","year":"2020","unstructured":"Peng X.; Sun Z.; Kuang P.; Chen J.; Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. Eur J Med Chem 2020,208,112831","journal-title":"Eur J Med Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejmech.2018.10.028","volume":"161","author":"Wang Y.","year":"2019","unstructured":"Wang Y.; He J.; Liao M.; Hu M.; Li W.; Ouyang H.; Wang X.; Ye T.; Zhang Y.; Ouyang L.; An overview of Sirtuins as potential therapeutic target: Structure, function and modulators. Eur J Med Chem 2019,161,48-77","journal-title":"Eur J Med Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1016\/j.bmc.2008.06.046","volume":"16","author":"Satyanarayana M.","year":"2008","unstructured":"Satyanarayana M.; Feng W.; Cheng L.; Liu A.A.; Tsai Y.C.; Liu L.F.; LaVoie E.J.; Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31). Bioorg Med Chem 2008,16(16),7824-7831","journal-title":"Bioorg Med Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-017-3334-5","volume":"80","author":"Cuya S.M.","year":"2017","unstructured":"Cuya S.M.; Bjornsti M.A.; van Waardenburg R.C.A.M.; DNA topoisomerase-targeting chemotherapeutics: What\u2019s new? Cancer Chemother Pharmacol 2017,80(1),1-14","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1021\/bi0021838","volume":"40","author":"Byl J.A.","year":"2001","unstructured":"Byl J.A.; Cline S.D.; Utsugi T.; Kobunai T.; Yamada Y.; Osheroff N.; DNA topoisomerase II as the target for the anticancer drug TOP-53: Mechanistic basis for drug action. Biochemistry 2001,40(3),712-718","journal-title":"Biochemistry"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"758","DOI":"10.2174\/156800910793605785","volume":"10","author":"Chikamori K.","year":"2010","unstructured":"Chikamori K.; Grozav A.G.; Kozuki T.; Grabowski D.; Ganapathi R.; Ganapathi M.K.; DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. Curr Cancer Drug Targets 2010,10(7),758-771","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","volume":"6","author":"Pommier Y.","year":"2006","unstructured":"Pommier Y.; Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer 2006,6(10),789-802","journal-title":"Nat Rev Cancer"},{"key":"ref=53","first-page":"1161","volume":"6","author":"Liang C.","year":"2014","unstructured":"Liang C.; X., J.; Song, Huihui; Zhou, Zhiguang; Xue, Yu; Yao, Qizheng Synthesis, in vitro and in vivo antitumor activity and docking studies of new vodiamine derivatives. J Chem Pharm Res 2014,6,1161-1171","journal-title":"J Chem Pharm Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"105154","DOI":"10.1016\/j.bioorg.2021.105154","volume":"114","author":"Fan X.","year":"2021","unstructured":"Fan X.; Deng J.; Shi T.; Wen H.; Li J.; Liang Z.; Lei F.; Liu D.; Zhang H.; Liang Y.; Hao X.; Wang Z.; Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma. Bioorg Chem 2021,114,105154","journal-title":"Bioorg Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"113960","DOI":"10.1016\/j.ejmech.2021.113960","volume":"228","author":"Liang Z.","year":"2022","unstructured":"Liang Z.; Lei F.; Deng J.; Zhang H.; Wang Y.; Li J.; Shi T.; Yang X.; Wang Z.; Design, synthesis and bioactivity evaluation of novel evodiamine derivatives with excellent potency against gastric cancer. Eur J Med Chem 2022,228,113960","journal-title":"Eur J Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"Jordan M.A.","year":"2004","unstructured":"Jordan M.A.; Wilson L.; Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004,4(4),253-265","journal-title":"Nat Rev Cancer"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"113930","DOI":"10.1016\/j.ejmech.2021.113930","volume":"228","author":"Cheng B.","year":"2022","unstructured":"Cheng B.; Zhu G.; Meng L.; Wu G.; Chen Q.; Ma S.; Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance. Eur J Med Chem 2022,228,113930","journal-title":"Eur J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1124\/mol.104.009043","volume":"67","author":"Belleri M.","year":"2005","unstructured":"Belleri M.; Ribatti D.; Nicoli S.; Cotelli F.; Forti L.; Vannini V.; Stivala L.A.; Presta M.; Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4\u2032-trimethoxystilbene. Mol Pharmacol 2005,67(5),1451-1459","journal-title":"Mol Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ejmech.2018.04.011","volume":"151","author":"Li L.","year":"2018","unstructured":"Li L.; Jiang S.; Li X.; Liu Y.; Su J.; Chen J.; Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site. Eur J Med Chem 2018,151,482-494","journal-title":"Eur J Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/ddr.21806","volume":"82","author":"Peng Y.","year":"2021","unstructured":"Peng Y.; Xiong R.; Li Z.; Peng J.; Xie Z.Z.; Lei X.Y.; He D.; Tang G.; Design, synthesis, and biological evaluation of 3\u2032,4\u2032,5\u2032-trimethoxy evodiamine derivatives as potential antitumor agents. Drug Dev Res 2021,82(7),1021-1032","journal-title":"Drug Dev Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"7593","DOI":"10.1021\/jm300605m","volume":"55","author":"Dong G.","year":"2012","unstructured":"Dong G.; Wang S.; Miao Z.; Yao J.; Zhang Y.; Guo Z.; Zhang W.; Sheng C.; New tricks for an old natural product: Discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. J Med Chem 2012,55(17),7593-7613","journal-title":"J Med Chem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1021\/acs.accounts.9b00292","volume":"52","author":"Stubelius A.","year":"2019","unstructured":"Stubelius A.; Lee S.; Almutairi A.; The chemistry of boronic acids in nanomaterials for drug delivery. Acc Chem Res 2019,52(11),3108-3119","journal-title":"Acc Chem Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ejmech.2019.06.092","volume":"179","author":"Fernandes G.F.S.","year":"2019","unstructured":"Fernandes G.F.S.; Denny W.A.; Dos Santos J.L.; Boron in drug design: Recent advances in the development of new therapeutic agents. Eur J Med Chem 2019,179,791-804","journal-title":"Eur J Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"13888","DOI":"10.1021\/ja5077684","volume":"136","author":"Kim E.J.","year":"2014","unstructured":"Kim E.J.; Bhuniya S.; Lee H.; Kim H.M.; Cheong C.; Maiti S.; Hong K.S.; Kim J.S.; An activatable prodrug for the treatment of metastatic tumors. J Am Chem Soc 2014,136(39),13888-13894","journal-title":"J Am Chem Soc"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1021\/jacs.8b13507","volume":"141","author":"Li J.","year":"2019","unstructured":"Li J.; Huang J.; Lyu Y.; Huang J.; Jiang Y.; Xie C.; Pu K.; photoactivatable organic semiconducting pro-nanoenzymes. J Am Chem Soc 2019,141(9),4073-4079","journal-title":"J Am Chem Soc"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/med.10043","volume":"23","author":"Yang W.","year":"2003","unstructured":"Yang W.; Gao X.; Wang B.; Boronic acid compounds as potential pharmaceutical agents. Med Res Rev 2003,23(3),346-368","journal-title":"Med Res Rev"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejmech.2016.03.063","volume":"116","author":"Wang L.","year":"2016","unstructured":"Wang L.; Xie S.; Ma L.; Chen Y.; Lu W.; 10-Boronic acid substituted camptothecin as prodrug of SN-38. Eur J Med Chem 2016,116,84-89","journal-title":"Eur J Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1021\/acsmedchemlett.9b00513","volume":"11","author":"Li X.","year":"2020","unstructured":"Li X.; Wu S.; Dong G.; Chen S.; Ma Z.; Liu D.; Sheng C.; Natural product evodiamine with borate trigger unit: Discovery of potent antitumor agents against colon cancer. ACS Med Chem Lett 2020,11(4),439-444","journal-title":"ACS Med Chem Lett"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1021\/acs.jmedchem.9b01626","volume":"63","author":"Wang L.","year":"2020","unstructured":"Wang L.; Fang K.; Cheng J.; Li Y.; Huang Y.; Chen S.; Dong G.; Wu S.; Sheng C.; Scaffold hopping of natural product evodiamine: Discovery of a novel antitumor scaffold with excellent potency against colon cancer. J Med Chem 2020,63(2),696-713","journal-title":"J Med Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"Baylin S.B.","year":"2011","unstructured":"Baylin S.B.; Jones P.A.; A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011,11(10),726-734","journal-title":"Nat Rev Cancer"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1517\/13543784.2014.857401","volume":"23","author":"Papavassiliou K.A.","year":"2014","unstructured":"Papavassiliou K.A.; Papavassiliou A.G.; Histone deacetylases inhibitors: Conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment. Expert Opin Investig Drugs 2014,23(3),291-294","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2217\/fon.11.2","volume":"7","author":"Thurn K.T.","year":"2011","unstructured":"Thurn K.T.; Thomas S.; Moore A.; Munster P.N.; Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011,7(2),263-283","journal-title":"Future Oncol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1248\/cpb.c20-00206","volume":"68","author":"Zou Y.","year":"2020","unstructured":"Zou Y.; Cao Z.; Wang J.; Chen X.; Chen Y.Q.; Li Y.; Liu J.; Zhao Y.; Wang A.; He B.; A series of novel HDAC inhibitors with anthraquinone as a cap group. Chem Pharm Bull (Tokyo) 2020,68(7),613-617","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=74","first-page":"7291","volume":"63","author":"Kim M.S.","year":"2003","unstructured":"Kim M.S.; Blake M.; Baek J.H.; Kohlhagen G.; Pommier Y.; Carrier F.; Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003,63(21),7291-7300","journal-title":"Cancer Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1677\/joe.1.06970","volume":"191","author":"Catalano M.G.","year":"2006","unstructured":"Catalano M.G.; Fortunati N.; Pugliese M.; Poli R.; Bosco O.; Mastrocola R.; Aragno M.; Boccuzzi G.; Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 2006,191(2),465-472","journal-title":"J Endocrinol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.apsb.2019.11.011","volume":"10","author":"Huang Y.","year":"2020","unstructured":"Huang Y.; Chen S.; Wu S.; Dong G.; Sheng C.; Evodiamine-inspired dual inhibitors of Histone Deacetylase 1 (HDAC1) and Topoisomerase 2 (TOP2) with potent antitumor activity. Acta Pharm Sin B 2020,10(7),1294-1308","journal-title":"Acta Pharm Sin B"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1039\/C4CS00373J","volume":"44","author":"Chen B.","year":"2015","unstructured":"Chen B.; Zang W.; Wang J.; Huang Y.; He Y.; Yan L.; Liu J.; Zheng W.; The chemical biology of sirtuins. Chem Soc Rev 2015,44(15),5246-5264","journal-title":"Chem Soc Rev"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nrm.2016.93","volume":"17","author":"Bonkowski M.S.","year":"2016","unstructured":"Bonkowski M.S.; Sinclair D.A.; Slowing ageing by design: The rise of NAD and sirtuin-activating compounds. Nat Rev Mol Cell Biol 2016,17(11),679-690","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/nrc3985","volume":"15","author":"Chalkiadaki A.","year":"2015","unstructured":"Chalkiadaki A.; Guarente L.; The multifaceted functions of sirtuins in cancer. Nat Rev Cancer 2015,15(10),608-624","journal-title":"Nat Rev Cancer"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1016\/j.bmc.2013.09.030","volume":"21","author":"Christodoulou M.S.","year":"2013","unstructured":"Christodoulou M.S.; Sacchetti A.; Ronchetti V.; Caufin S.; Silvani A.; Lesma G.; Fontana G.; Minicone F.; Riva B.; Ventura M.; Lahtela-Kakkonen M.; Jarho E.; Zuco V.; Zunino F.; Martinet N.; Dapiaggi F.; Pieraccini S.; Sironi M.; Dalla Via L.; Gia O.M.; Passarella D.; Quinazolinecarboline alkaloid evodiamine as scaffold for targeting topoisomerase I and sirtuins. Bioorg Med Chem 2013,21(22),6920-6928","journal-title":"Bioorg Med Chem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1021\/ml500327q","volume":"6","author":"He S.","year":"2015","unstructured":"He S.; Dong G.; Wang Z.; Chen W.; Huang Y.; Li Z.; Jiang Y.; Liu N.; Yao J.; Miao Z.; Zhang W.; Sheng C.; Discovery of novel multiacting topoisomerase i\/ii and histone deacetylase inhibitors. ACS Med Chem Lett 2015,6(3),239-243","journal-title":"ACS Med Chem Lett"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"6678","DOI":"10.1021\/acs.jmedchem.5b00910","volume":"58","author":"Wang S.","year":"2015","unstructured":"Wang S.; Fang K.; Dong G.; Chen S.; Liu N.; Miao Z.; Yao J.; Li J.; Zhang W.; Sheng C.; Scaffold diversity inspired by the natural product evodiamine: Discovery of highly potent and multitargeting antitumor agents. J Med Chem 2015,58(16),6678-6696","journal-title":"J Med Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"113544","DOI":"10.1016\/j.ejmech.2021.113544","volume":"220","author":"Chen S.","year":"2021","unstructured":"Chen S.; Bi K.; Wu S.; Li Y.; Huang Y.; Sheng C.; Dong G.; Water-soluble derivatives of evodiamine: Discovery of evodiamine-10-phosphate as an orally active antitumor lead compound. Eur J Med Chem 2021,220,113544","journal-title":"Eur J Med Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/156800909787581015","volume":"9","author":"Mocellin S.","year":"2009","unstructured":"Mocellin S.; Nitric oxide: Cancer target or anticancer agent? Curr Cancer Drug Targets 2009,9(2),214-236","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1039\/c2cs15273h","volume":"41","author":"Carpenter A.W.","year":"2012","unstructured":"Carpenter A.W.; Schoenfisch M.H.; Nitric oxide release: Part II. Therapeutic applications. Chem Soc Rev 2012,41(10),3742-3752","journal-title":"Chem Soc Rev"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nm0503-496","volume":"9","author":"Gladwin M.T.","year":"2003","unstructured":"Gladwin M.T.; Lancaster J.R.; Freeman B.A.; Schechter A.N.; Nitric oxide\u2019s reactions with hemoglobin: A view through the SNO-storm. Nat Med 2003,9(5),496-500","journal-title":"Nat Med"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.niox.2008.04.016","volume":"19","author":"Pervin S.","year":"2008","unstructured":"Pervin S.; Singh R.; Chaudhuri G.; Nitric oxide, N omega-hydroxy-L-arginine and breast cancer. Nitric Oxide 2008,19(2),103-106","journal-title":"Nitric Oxide"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1021\/mp5003009","volume":"11","author":"Song Q.","year":"2014","unstructured":"Song Q.; Tan S.; Zhuang X.; Guo Y.; Zhao Y.; Wu T.; Ye Q.; Si L.; Zhang Z.; Nitric oxide releasing d-&#x3B1;-tocopheryl polyethylene glycol succinate for enhancing antitumor activity of doxorubicin. Mol Pharm 2014,11(11),4118-4129","journal-title":"Mol Pharm"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1021\/jm400463q","volume":"56","author":"Han C.","year":"2013","unstructured":"Han C.; Huang Z.; Zheng C.; Wan L.; Zhang L.; Peng S.; Ding K.; Ji H.; Tian J.; Zhang Y.; Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer. J Med Chem 2013,56(11),4738-4748","journal-title":"J Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1021\/jm5019302","volume":"58","author":"Ai Y.","year":"2015","unstructured":"Ai Y.; Kang F.; Huang Z.; Xue X.; Lai Y.; Peng S.; Tian J.; Zhang Y.; Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer. J Med Chem 2015,58(5),2452-2464","journal-title":"J Med Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"9343","DOI":"10.1021\/jm500613m","volume":"57","author":"Liu M.M.","year":"2014","unstructured":"Liu M.M.; Chen X.Y.; Huang Y.Q.; Feng P.; Guo Y.L.; Yang G.; Chen Y.; Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents. J Med Chem 2014,57(22),9343-9356","journal-title":"J Med Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1016\/j.bmc.2016.05.001","volume":"24","author":"Zhao N.","year":"2016","unstructured":"Zhao N.; Tian K.T.; Cheng K.G.; Han T.; Hu X.; Li D.H.; Li Z.L.; Hua H.M.; Antiproliferative activity and apoptosis inducing effects of nitric oxide donating derivatives of evodiamine. Bioorg Med Chem 2016,24(13),2971-2978","journal-title":"Bioorg Med Chem"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nrd.2015.1","volume":"15","author":"Szabo C.","year":"2016","unstructured":"Szabo C.; Gasotransmitters in cancer: From pathophysiology to experimental therapy. Nat Rev Drug Discov 2016,15(3),185-203","journal-title":"Nat Rev Drug Discov"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-3-319-18144-8_12","volume":"230","author":"Hellmich M.R.","year":"2015","unstructured":"Hellmich M.R.; Szabo C.; Hydrogen sulfide and cancer. Handb Exp Pharmacol 2015,230,233-241","journal-title":"Handb Exp Pharmacol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1021\/acs.jmedchem.6b00184","volume":"59","author":"Chegaev K.","year":"2016","unstructured":"Chegaev K.; Rolando B.; Cortese D.; Gazzano E.; Buondonno I.; Lazzarato L.; Fanelli M.; Hattinger C.M.; Serra M.; Riganti C.; Fruttero R.; Ghigo D.; Gasco A.; H2S-Donating doxorubicins may overcome cardiotoxicity and multidrug resistance. J Med Chem 2016,59(10),4881-4889","journal-title":"J Med Chem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1021\/acs.jmedchem.5b00848","volume":"58","author":"Feng W.","year":"2015","unstructured":"Feng W.; Teo X.Y.; Novera W.; Ramanujulu P.M.; Liang D.; Huang D.; Moore P.K.; Deng L.W.; Dymock B.W.; Discovery of new H2S releasing phosphordithioates and 2,3-dihydro-2-phenyl-2-sulfanylenebenzo[d][1,3,2]oxazaphospholes with improved antiproliferative activity. J Med Chem 2015,58(16),6456-6480","journal-title":"J Med Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3389\/fphar.2017.00664","volume":"8","author":"Yang C.T.","year":"2017","unstructured":"Yang C.T.; Chen L.; Xu S.; Day J.J.; Li X.; Xian M.; Recent development of hydrogen sulfide releasing\/stimulating reagents and their potential applications in cancer and glycometabolic disorders. Front Pharmacol 2017,8,664","journal-title":"Front Pharmacol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.phrs.2016.10.019","volume":"114","author":"De Cicco P.","year":"2016","unstructured":"De Cicco P.; Panza E.; Ercolano G.; Armogida C.; Sessa G.; Pirozzi G.; Cirino G.; Wallace J.L.; Ianaro A.; \nATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development \nin vivo\n.\n Pharmacol Res 2016,114,67-73","journal-title":"Pharmacol Res"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.phrs.2016.07.041","volume":"111","author":"Ianaro A.","year":"2016","unstructured":"Ianaro A.; Cirino G.; Wallace J.L.; Hydrogen sulfide-releasing anti-inflammatory drugs for chemoprevention and treatment of cancer. Pharmacol Res 2016,111,652-658","journal-title":"Pharmacol Res"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/mabi.201500156","volume":"15","author":"Hasegawa U.","year":"2015","unstructured":"Hasegawa U.; Tateishi N.; Uyama H.; van der Vlies A.J.; Hydrolysis-sensitive dithiolethione prodrug micelles. Macromol Biosci 2015,15(11),1512-1522","journal-title":"Macromol Biosci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ejmech.2018.04.009","volume":"151","author":"Hu X.","year":"2018","unstructured":"Hu X.; Jiao R.; Li H.; Wang X.; Lyu H.; Gao X.; Xu F.; Li Z.; Hua H.; Li D.; Antiproliferative hydrogen sulfide releasing evodiamine derivatives and their apoptosis inducing properties. Eur J Med Chem 2018,151,376-388","journal-title":"Eur J Med Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"15750","DOI":"10.3390\/molecules181215750","volume":"18","author":"Song S.","year":"2013","unstructured":"Song S.; Chen Z.; Li S.; Huang Y.; Wan Y.; Song H.; Design, synthesis and evaluation of N13-substituted evodiamine derivatives against human cancer cell lines. Molecules 2013,18(12),15750-15768","journal-title":"Molecules"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"e99729","DOI":"10.1371\/journal.pone.0099729","volume":"9","author":"Chien C.C.","year":"2014","unstructured":"Chien C.C.; Wu M.S.; Shen S.C.; Ko C.H.; Chen C.H.; Yang L.L.; Chen Y.C.; Activation of JNK contributes to evodiamine-induced apoptosis and G2\/M arrest in human colorectal carcinoma cells: A structure-activity study of evodiamine. PLoS One 2014,9(6),e99729","journal-title":"PLoS One"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ejmech.2018.04.001","volume":"151","author":"Singh R.K.","year":"2018","unstructured":"Singh R.K.; Kumar S.; Prasad D.N.; Bhardwaj T.R.; Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives. Eur J Med Chem 2018,151,401-433","journal-title":"Eur J Med Chem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1016\/j.bmcl.2017.10.014","volume":"27","author":"Hu X.","year":"2017","unstructured":"Hu X.; Wang Y.; Xue J.; Han T.; Jiao R.; Li Z.; Liu W.; Xu F.; Hua H.; Li D.; Design and synthesis of novel nitrogen mustard-evodiamine hybrids with selective antiproliferative activity. Bioorg Med Chem Lett 2017,27(22),4989-4993","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"117996","DOI":"10.1016\/j.lfs.2020.117996","volume":"256","author":"Abeysinghe A.A.D.T.","year":"2020","unstructured":"Abeysinghe A.A.D.T.; Deshapriya R.D.U.S.; Udawatte C.; Alzheimer\u2019s disease; a review of the pathophysiological basis and therapeutic interventions. Life Sci 2020,256,117996","journal-title":"Life Sci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.2174\/092986711797200435","volume":"18","author":"Mohamed T.","year":"2011","unstructured":"Mohamed T.; Rao P.P.; Alzheimer\u2019s disease: Emerging trends in small molecule therapies. Curr Med Chem 2011,18(28),4299-4320","journal-title":"Curr Med Chem"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1568026619666191203113745","volume":"20","author":"Xie J.","year":"2020","unstructured":"Xie J.; Liang R.; Wang Y.; Huang J.; Cao X.; Niu B.; Progress in target drug molecules for Alzheimer\u2019s disease. Curr Top Med Chem 2020,20(1),4-36","journal-title":"Curr Top Med Chem"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1358\/dot.2009.045.004.1353853","volume":"45","author":"Adlard P.A.","year":"2009","unstructured":"Adlard P.A.; James S.A.; Bush A.I.; Masters C.L.; beta-Amyloid as a molecular therapeutic target in Alzheimer\u2019s disease. Drugs Today (Barc) 2009,45(4),293-304","journal-title":"Drugs Today (Barc)"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.neubiorev.2011.03.001","volume":"35","author":"Craig L.A.","year":"2011","unstructured":"Craig L.A.; Hong N.S.; McDonald R.J.; Revisiting the cholinergic hypothesis in the development of Alzheimer\u2019s disease. Neurosci Biobehav Rev 2011,35(6),1397-1409","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejmech.2014.05.002","volume":"81","author":"Huang G.","year":"2014","unstructured":"Huang G.; Kling B.; Darras F.H.; Heilmann J.; Decker M.; Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine. Eur J Med Chem 2014,81,15-21","journal-title":"Eur J Med Chem"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ame2.12126","volume":"3","author":"Pang S.","year":"2020","unstructured":"Pang S.; Sun C.; Gao S.; Yang Y.; Pan X.; Zhang L.; Evodiamine derivatives improve cognitive abilities in APP\/PS1 transgenic mouse models of Alzheimer\u2019s disease. Animal Model Exp Med 2020,3(2),193-199","journal-title":"Animal Model Exp Med"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"Bender A.T.","year":"2006","unstructured":"Bender A.T.; Beavo J.A.; Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 2006,58(3),488-520","journal-title":"Pharmacol Rev"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/med.20053","volume":"26","author":"Pissarnitski D.","year":"2006","unstructured":"Pissarnitski D.; \nPhosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: Attaining selectivity \nversus\nPDE6.\n Med Res Rev 2006,26(3),369-395","journal-title":"Med Res Rev"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"Maurice D.H.","year":"2014","unstructured":"Maurice D.H.; Ke H.; Ahmad F.; Wang Y.; Chung J.; Manganiello V.C.; Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014,13(4),290-314","journal-title":"Nat Rev Drug Discov"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","volume":"18","author":"Baillie G.S.","year":"2019","unstructured":"Baillie G.S.; Tejeda G.S.; Kelly M.P.; Therapeutic targeting of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases: Inhibition and beyond. Nat Rev Drug Discov 2019,18(10),770-796","journal-title":"Nat Rev Drug Discov"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-pharmtox-010716-104756","volume":"57","author":"Kokkonen K.","year":"2017","unstructured":"Kokkonen K.; Kass D.A.; Nanodomain regulation of cardiac cyclic nucleotide signaling by phosphodiesterases. Annu Rev Pharmacol Toxicol 2017,57,455-479","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.abb.2014.07.003","volume":"563","author":"Rodr\u00edguez C.I.","year":"2014","unstructured":"Rodr\u00edguez C.I.; Setaluri V.; Cyclic AMP (cAMP) signaling in melanocytes and melanoma. Arch Biochem Biophys 2014,563,22-27","journal-title":"Arch Biochem Biophys"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrd893","volume":"1","author":"Rotella D.P.","year":"2002","unstructured":"Rotella D.P.; Phosphodiesterase 5 inhibitors: Current status and potential applications. Nat Rev Drug Discov 2002,1(9),674-682","journal-title":"Nat Rev Drug Discov"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/emboj\/cdg051","volume":"22","author":"Rybalkin S.D.","year":"2003","unstructured":"Rybalkin S.D.; Rybalkina I.G.; Shimizu-Albergine M.; Tang X.B.; Beavo J.A.; PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 2003,22(3),469-478","journal-title":"EMBO J"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"12051","DOI":"10.1074\/jbc.M413611200","volume":"280","author":"Zoraghi R.","year":"2005","unstructured":"Zoraghi R.; Bessay E.P.; Corbin J.D.; Francis S.H.; Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 2005,280(12),12051-12063","journal-title":"J Biol Chem"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"38149","DOI":"10.1074\/jbc.M110.141614","volume":"285","author":"Wang H.","year":"2010","unstructured":"Wang H.; Robinson H.; Ke H.; Conformation changes, N-terminal involvement, and cGMP signal relay in the phosphodiesterase-5 GAF domain. J Biol Chem 2010,285(49),38149-38156","journal-title":"J Biol Chem"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"21469","DOI":"10.1074\/jbc.M512527200","volume":"281","author":"Wang H.","year":"2006","unstructured":"Wang H.; Liu Y.; Huai Q.; Cai J.; Zoraghi R.; Francis S.H.; Corbin J.D.; Robinson H.; Xin Z.; Lin G.; Ke H.; Multiple conformations of phosphodiesterase-5: Implications for enzyme function and drug development. J Biol Chem 2006,281(30),21469-21479","journal-title":"J Biol Chem"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"6622","DOI":"10.1021\/acs.jmedchem.7b00523","volume":"60","author":"Wu D.","year":"2017","unstructured":"Wu D.; Zhang T.; Chen Y.; Huang Y.; Geng H.; Yu Y.; Zhang C.; Lai Z.; Wu Y.; Guo X.; Chen J.; Luo H.B.; Discovery and optimization of chromeno[2,3-c]pyrrol-9(2H)-ones as novel selective and orally bioavailable phosphodiesterase 5 inhibitors for the treatment of pulmonary arterial hypertension. J Med Chem 2017,60(15),6622-6637","journal-title":"J Med Chem"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"9828","DOI":"10.1021\/acs.jmedchem.0c00983","volume":"63","author":"Zhang T.","year":"2020","unstructured":"Zhang T.; Lai Z.; Yuan S.; Huang Y.Y.; Dong G.; Sheng C.; Ke H.; Luo H.B.; Discovery of evodiamine derivatives as highly selective PDE5 inhibitors targeting a unique allosteric pocket. J Med Chem 2020,63(17),9828-9837","journal-title":"J Med Chem"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev.biochem.75.103004.142819","volume":"76","author":"Venkatachalam K.","year":"2007","unstructured":"Venkatachalam K.; Montell C.; TRP channels. Annu Rev Biochem 2007,76,387-417","journal-title":"Annu Rev Biochem"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrd2757","volume":"8","author":"Patapoutian A.","year":"2009","unstructured":"Patapoutian A.; Tate S.; Woolf C.J.; Transient receptor potential channels: Targeting pain at the source. Nat Rev Drug Discov 2009,8(1),55-68","journal-title":"Nat Rev Drug Discov"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2174\/1874467210801030255","volume":"1","author":"Jara-Oseguera A.","year":"2008","unstructured":"Jara-Oseguera A.; Simon S.A.; Rosenbaum T.; TRPV1: On the road to pain relief. Curr Mol Pharmacol 2008,1(3),255-269","journal-title":"Curr Mol Pharmacol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","volume":"139","author":"Basbaum A.I.","year":"2009","unstructured":"Basbaum A.I.; Bautista D.M.; Scherrer G.; Julius D.; Cellular and molecular mechanisms of pain. Cell 2009,139(2),267-284","journal-title":"Cell"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1111\/bph.12320","volume":"171","author":"De Petrocellis L.","year":"2014","unstructured":"De Petrocellis L.; Schiano Moriello A.; Fontana G.; Sacchetti A.; Passarella D.; Appendino G.; Di Marzo V.; Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels. Br J Pharmacol 2014,171(10),2608-2620","journal-title":"Br J Pharmacol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"113937","DOI":"10.1016\/j.ejmech.2021.113937","volume":"227","author":"Yang C.J.","year":"2022","unstructured":"Yang C.J.; Li H.X.; Wang J.R.; Zhang Z.J.; Wu T.L.; Liu Y.Q.; Tang C.; Chu Q.R.; Du S.S.; He Y.H.; Design, synthesis and biological evaluation of novel evodiamine and rutaecarpine derivatives against phytopathogenic fungi. Eur J Med Chem 2022,227,113937","journal-title":"Eur J Med Chem"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ejpb.2014.06.007","volume":"88","author":"Hu J.","year":"2014","unstructured":"Hu J.; Sun L.; Zhao D.; Zhang L.; Ye M.; Tan Q.; Fang C.; Wang H.; Zhang J.; Supermolecular evodiamine loaded water-in-oil nanoemulsions: Enhanced physicochemical and biological characteristics. Eur J Pharm Biopharm 2014,88(2),556-564","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1208\/s12249-012-9772-9","volume":"13","author":"Tan Q.","year":"2012","unstructured":"Tan Q.; Liu S.; Chen X.; Wu M.; Wang H.; Yin H.; He D.; Xiong H.; Zhang J.; Design and evaluation of a novel evodiamine-phospholipid complex for improved oral bioavailability. AAPS PharmSciTech 2012,13(2),534-547","journal-title":"AAPS PharmSciTech"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557522666220404090835","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/203038\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557522666220404090835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T02:18:35Z","timestamp":1669774715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/203038\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":133,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557522666220404090835","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}